anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Lower gastrointestinal bleeding (LGIB) is a common reason for emergency department visits and subsequent hospitalizations. Recent data suggests that low-risk patients may be safely evaluated as an outpatient. Recommendations for healthcare systems to identify low-risk patients who can be safely discharged with timely outpatient follow-up have yet to be established. The primary objective of this study was to determine the role of patient predictors for the patients with LGIB to receive urgent endoscopic intervention.
METHODS: A retrospective chart review was performed on 142 patients. Data was collected on patient demographics, clinical features, comorbidities, medications, hemodynamic parameters, laboratory values, and diagnostic imaging. Logistic regression analysis, independent samples t-testing, Mann Whitney U testing for non-parametric data, and univariate analysis of categorical variables by Chi square test was performed to determine relationships within the data.
RESULTS: On logistic regression analysis, A hemoglobin drop of > 20 g/L was the only variable that predicted endoscopic intervention (p = 0.030). Tachycardia, hypotension, or presence of anticoagulation were not significantly associated with endoscopic intervention (p > 0.05).
CONCLUSIONS: A hemoglobin drop of > 20 g/L was the only patient parameter that predicted the need for urgent endoscopic intervention in the emergency department.
The invention relates to a method for treating ischemic diseases of lower limbs by stem cells. The cell therapy composition for treating ischemic diseases of lower limbs comprises: umbilical cord mesenchymal stem cells, sodium chloride, and water. The cell therapy composition is prepared as follows: dissolving sodium chloride in water, optionally sterilizing the solution to obtain matrix; suspending the prepared mesenchymal stem cells in the matrix, and packaging. The invention also relates to a method for preparing said cell therapy compositions, and to their medical use. The method of the present invention exhibits excellent technical effects as described in the specification, for example, the composition obtained by the present invention exhibits excellent cell recovery performance during cell recovery, and the viability of cells undergoing recovery process and the survival stability of cells after recovery are significantly higher than those of the prior art solutions. In addition, the compositions of the present invention exhibit more beneficial biological activity.
Midazolam in Sodium Chloride Injection is a benzodiazepine available as a sterile, preservative-free, nonpyrogenic solution of midazolam and sodium chloride in water for injection for intravenous use. Each single-dose bag of Midazolam in Sodium Chloride Injection contains either 50 mg/50 mL (1 mg/mL) or 100 mg/100 mL (1 mg/mL) of midazolam and 9 mg/mL of sodium chloride in water for injection. Midazolam in Sodium Chloride Injection may contain hydrochloric acid and/or sodium hydroxide for pH adjustment. The pH is approximately 2.5 to 3.5.

Midazolam is a white to light yellow crystalline compound, insoluble in water, freely soluble in ethanol, soluble in methanol. Chemically, midazolam is 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine. Midazolam has the empirical formula C18H13ClFN3, a calculated molecular weight of 325.77 and the following structural formula:

Midazolam structure
The invention discloses peppermint essential oil bath salts. The peppermint essential oil bath salts comprise components in parts by weight as follows: 30-50 parts of sea salt, 10-30 parts of sodium sulfate, 10-30 parts of monosodium phosphate, 5-10 parts of pearl powder, 5-10 parts of dry aloe gel, 1-5 parts of sodium carboxymethyl inulin, 1-5 parts of cocamidopropyl betaine, 1-5 parts of sodium laneth sulfate, 0.5-3 parts of peppermint essential oil, 0.5-3 parts of eucalyptus oil, 1-5 parts of spearmint essential oil. A preparation method of the peppermint essential oil bath salts comprises following steps: 1 preparation of the dry aloe gel; 2 essential oil absorption by the pearl powder; 3 preparation of the peppermint essential oil bath salts. The peppermint essential oil bath salts are light green, can generate rich foam when added to water and has very good cool and refreshing feeling and an uplifting function. An aqueous solution is faintly acid to neutral and does not damage the skin. The peppermint essential oil bath salts have very good moisturizing and whitening functions and can be used for a long time.
Being a parent to a premature infant in NICU is an anxious state. Parents ask a lot of questions, and look for information all the time. Organizing the information given to parents could reduce their anxiety. The parents will be divided into two groups: one group will get organized information, by a lecture at the first week of their infant's life, and the other group will not. Of course, questions will be answered all the time. The parents will answer a questionnaire on the first week of the infant's life, and on the last week, just before releasing the infant home.
Participants received 112 mg (four 28 mg capsules) of TIP administered by the T-326 Inhaler, twice a day (b.i.d.), given in a cycle of 28 days on treatment followed by 28 days off treatment (one cycle = 56 days) for up to 3 cycles.
<P>PROBLEM TO BE SOLVED: To provide an easily producible food material having improved safety and high effectiveness, exhibiting TNF production promoting activity and easy to use and to prevent the infection with bacteria and viruses.  <P>SOLUTION: A water-soluble heteropolysaccharide produced by an acetobacter (e.g. Acetobacter polysaccharogenes and Acetobacter xylinum) and containing at least glucose, mannose and glucuronic acid as constituent sugars is used as an active component of the composition inducing the production of tumor necrosis factor. The water-soluble heteropolysaccharide produced by acetobacter for the production of food vinegar and having high safety is found to have an activity to induce the production of tumor necrosis factor. The composition for inducing the production of tumor necrosis factor and produced based on the finding has improved safety and is usable as foods, drinks and health food materials and pharmaceuticals.  <P>COPYRIGHT: (C)2004,JPO
501,752. Preparations for treating the scalp. OVERILL, S. Sept. 3, 1937, No. 24103. [Class 81 (i)] A preparation for promoting the growth of hair comprises an animal fat (or fats), an extract of bran, vegetable oil, finely divided sulphur and a volatile solvent. The animal fat may be mixed with the bran and cooked with a small proportion of water. The fatty fraction so obtained being separated and mixed with vegetable oil, sulphur and the solvent. A proportion of hard wax, e.g. paraffin wax, and essential oil may be added. In an example, the fat comprises a mixture of beef and pig fat, the oil is castor oil and the solvent absolute alcohol.
Participants will be asked to use the remote monitoring devices twice a week, on mutually agreed days for a minimum of 30 minutes each time. Ideally participants will use the home CTG monitor for at least a four-week period or until delivery.
The present invention relates to an artificial intelligence-based cervical artificial disc modeling apparatus and a method thereof. A learning model for estimating positions of a plurality of landmarks is generated by learning medical images of various shapes to which the plurality of landmarks are assigned. The landmarks constitute an available space in which cervical discs are located. The plurality of landmarks are estimated by inputting input data into the generated learning model. The input data is generated from the medical images of the available space in which a cervical artificial disc to be operated is located. The available space into which the cervical artificial disc to be operated is inserted is generated according to the estimated landmarks. In the generated available space, shape information about surfaces and edges of the artificial discs is extracted from the medical image and reflected. Also, a model of the cervical artificial discs to be operated is generated and output.
The invention discloses interleukin-17 (IL-17) receptor antagonist which is characterized in that: the antagonist is peptide; the amino acid sequence of the peptide comprises a sequence with the number being SEQ ID No. 1 and the sequence with the number being SEQ ID No. 2 which are connected through a flexible connecting sequence; and the connecting order is sequentially the SEQ ID No. 1 sequence, the connecting sequence and the SEQ ID No. 2 sequence from a nitrogen end to a carbon end. According to the invention, IL-17RA PLAD and IgG Fc sections with the specificity existing in the IL-17 receptor form soluble fusion protein, are connected by flexible connecting protein Linker, do not affect the secondary structure of the protein, and can be separated and purified targeting at Ig. Consequently, the IL-17RAPLAD is closed, and the oligosaccharide of the receptor is suppressed. The interleukin-17 (IL-17) receptor antagonist has the advantages of high specificity, high blocking efficiency and the like.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting primarily motor neurons, for which treatment designed to slow or arrest progression remains lacking. Mexiletine is a use-dependent sodium channel blocker that has been FDA-approved for decades for the treatment of cardiac arrhythmias and more recently to treat neuropathic pain in diabetic polyneuropathy. Mexiletine has been shown also to be protective of neurons following spinal cord, head injury, and cerebral ischemia, largely by blocking excitotoxicity. Based on previous studies, mexiletine appears to penetrate into the central nervous system at concentrations sufficient to confer significant protection. Recent unpublished studies in the laboratory of Dr. Robert Brown at the University of Massachusetts have also demonstrated that mexiletine ingestion in mice genetically engineered to express high levels of mutant cytosolic copper-zinc superoxide dismutase-1 (SOD1) transgene prolongs survival in these animals. As mexiletine already has FDA-approval as an anti-arrhythmic agent, much is known about the pharmacology and safety of this drug in non-ALS patients. We anticipate that by excluding subjects with a known history of cardiac disease and with the known neuroprotectant properties of this medication, mexiletine is a good choice for further study in an ALS clinical trial.
OBJECTIVES: The COVID-19 pandemic has had substantial impacts for both people using pain services and healthcare professionals delivering them. While the effects on service users have been studied, less is known about the effects for service providers. This study aimed to assess the impact of the pandemic on providers and the evolving role of telemedicine in treatment.
DESIGN & METHODS: An electronic survey was distributed to the professional membership of the European Pain Federation (EFIC). The survey evaluated impact and adjustment to the COVID-19 pandemic separately across two pandemic years (March 2020-February 2021 and March 2021 to February 2022) and assessed worry about COVID-19, disruption and adjustment of pain services, and use of telehealth services. The change between the first and second pandemic years and the degree to which telehealth services were adopted was evaluated.
RESULTS: From 149 respondents, 131 (88%) participants provided sufficient data to be included in the analysis. Both providers worry about the pandemic and service disruption decreased significantly from the first to the second year of the pandemic. Prior to the pandemic, only 30% of providers offered telehealth appointments but this increased to 64% and 83%, respectively, in the first and second years of the pandemic.
CONCLUSIONS: Although provider worry and disruption to delivery of pain services decreased during the second year of COVID-19 pandemic, waiting times for appointments continued to lengthen. The pandemic has hastened the adoption of telemedicine in pain services and plans to continue telehealth services seem common.
Composition with a milled grain product, comprises a carbohydrate portion of less than 15 wt. % and an omega-3-fatty acid content of at least 2 wt. %. An independent claim is included for a baked product containing the composition. ACTIVITY : Cytostatic; Antidiabetic; Neuroprotective; Nootropic. MECHANISM OF ACTION : None given.
• Octreotide acetate injection may be administered subcutaneously or intravenously. Pain with subcutaneous administration may be reduced by using the smallest volume that will deliver the desired dose. Sites should be rotated in a systematic manner.  
• Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if particulates and/or discoloration are observed. Octreotide acetate injection is not compatible in Total Parenteral Nutrition solutions because of the formation of a glycosyl octreotide conjugate which may decrease the efficacy of the product.  
• Octreotide acetate injection may be diluted in volumes of 50 mL to 200 mL and infused intravenously over 15 to 30 minutes or administered by intravenous (IV) push over 3 minutes. In emergency situations (e.g., carcinoid crisis), it may be given by rapid bolus.  
• Assess total and/or free T4 levels at baseline and periodically during chronic octreotide acetate therapy.
In Switzerland, the number of overweight children \<18 years is estimated to 80'000 and related cardiovascular, osteoarticular and other complications are already present in approximately in 50% of these youth. Controlled studies demonstrated that multiprofessional treatment programs can reduce adiposity and improve health risk factors. To pre-empt the deterioration of obesity and co-morbidities in adult life, the Swiss Department of the Interior (EDI) approved in 2007 the reimbursement of treatment of overweight children by health insurances , if conducted in certified multi-professional family-based group programs. All programs have to participate in a scientific evaluation study supported by the Federal Office of Public Health (FOPH) in order to determine nationwide outcomes in clinical practice. The goal of this study is to evaluate individual changes of physical activity, nutrition, behaviours, quality of life, co-morbidities and adiposity during therapy and to identify predictors of positive or negative changes.

During 5 years, the investigators will recruit about 200 children and adolescents aged 6 to 18 years every year. Patients must have a Body Mass Index (BMI), fat mass or waist circumference above the 97th percentile, or a BMI above the 90th percentile plus a co-morbidity. Together with their parents they will be enrolled in an intensive group therapy program for 6 to 12 months, with 12 months of follow up. To date, in 25 certified centres, physicians, nutrition and physical activity specialists as well as psychologists can provide a multiprofessional standardized care, the costs of participation being reimbursed after regular presence. At start, after 1 year and 2 years, standardized instruments validated in Swiss or European children will be used to document changes during therapy. Questionnaires will assess motivation, weight of parents, personal and family history, quality of life, child and family lifestyle, parenting skills, eating or psychological disorders, and satisfaction. Other investigations will include medical examination, blood tests, and European Fitness (\*Eurofit\*)-test for physical fitness and capacities. Anonymised data will be recorded centrally in an electronic database, after controlling for completeness and plausibility. Informed consent and positive votes of local ethical committees will be obtained. Reports on cross-sectional and longitudinal descriptive statistics and benchmarking will be provided once yearly. A comprehensive multivariate analysis of complex associations between predictors and health-related outcomes will be completed. Statistical analyses will be performed by specialists in each field and will be supervised by public health scientists. To guarantee meaningful analyses, the last patients will be included in December 2013.
The present invention relates to a kind of pueraria series health-care products and its preparation method. The pueraraia powder, pueraria juice, fruit and vegetable juice and xylitol, etc. as main components are respectively mixed, and can be made into three kinds of different liquor beverages and solid soluble powder preparation. Firstly, the pueraria root can be undergone the procedures of cleaning, pulverizing, filtering, stirring, homogenizing and instantaneous high-temp. sterilization to implement its production process. Said product contains pueraria flavone with several health-care functions, its pueraria total flavone content can be up to 18.26 mg/100ml. It can increase cardio-cerebral vessel blood flow rate, regulating blood pressure and reducing blood fat and blood cholesterol.
BACKGROUND: The evolving and unpredictable unregulated drug market has driven an unprecedented overdose crisis that requires effective intervention. Growing evidence suggests that novel opioid agonist treatments, such as tablet injectable opioid agonist therapy (TiOAT), have potential to prevent overdoses and other drug-related harms. More evidence is needed to characterize their utility in achieving these outcomes. The current article is an analysis of two TiOAT programs implemented in British Columbia, Canada, to assess impact on health and well-being, including overdose risk. Moreover, we explored participants' enrollment goals and if they were achieved.
METHODS: The study employed qualitative methods to evaluate the TiOAT program in two sites between October 2021 and April 2022. We developed a semi-structured interview tool to guide in depth interviews. All interviews (n = 32) took place on teleconference software or in person. Thematic analysis allowed for the emergence of themes associated with TiOAT participation.
RESULTS: Participants discussed various motivations for enrolling in TiOAT, which included gaining financial stability, reducing or eliminating drug use, addressing withdrawal symptoms, wanting to work, and improving social circumstances. An assessment of initial programmatic impacts revealed that many participant-identified motivators were achieved. Participants also reported fewer or no overdoses since starting TiOAT, and many reported switching from injecting to smoking drugs. Some challenges included adequate dosing as evidenced by ongoing withdrawal and pain. Some participants requested additional opioids, such as diacetylmorphine, to aid in reducing illicit drug use.
CONCLUSION: Participants described how TiOAT helped them to achieve many of their goals. Suggested programmatic improvements include enhanced patient-provider co-design with respect to dosing to address ongoing withdrawal and pain. As the unpredictability the unregulated drug market worsens, novel options, such as TiOAT, ought to be implemented broadly to reduce overdose events and improve quality of life for people who use drugs.
PROBLEM TO BE SOLVED: To efficiently prepare a gel-like composition by using calcium ascorbate capable of exhibiting a gel-forming action in a proper concentration. SOLUTION: This method for preparing a gel-like composition, preferably alginic acid gel, comprises using calcium ascorbate as a gelling agent. The gel-like composition preferably contains chitosan or its salt. For example, a gel-like composition can be obtained in one step by mixing an aqueous solution of a substance having a gelling ability (preferably sodium alginate) with an aqueous calcium ascorbate solution containing an organic acid (preferably lactic acid, ascorbic acid, gluconic acid, or the like). When reduced ascorbic acid or its salt is used as a gelling agent, the oxidative deterioration of a substance contained in the prepared gel beads can be prevented. Thereby, the gelling agent does not require its washing away after gelled in the gel-like composition, and can be used as a vitamin preparation.
Post infarction heart failure (HF) remains a major cause of morbidity and mortality. In the United States, more than three million patients, and 700.000 in Italy, have cardiac failure and its most common cause is ischemic heart disease. The major goal to improve post infarction LV function would be the stimulation of neovascularization and the enhancement of regeneration of cardiac myocytes within the infarcted area. Recent experimental studies suggest that bone marrow-derived progenitor cells (BMCs) or circulating endothelial progenitor cells (cEPCs) contribute to the regeneration of infarcted myocardium, to enhance neovascularization of ischemic myocardium, to prevent cardiomyocyte apoptosis, to alter scar formation by reducing the development of myocardial fibrosis and, thereby, to improve cardiac function.

G-CSF is a hematopoietic cytokine produced by monocytes, fibroblasts and endothelial cells. G-CSF is known to have multiple functions in normal, steady-state hematopoiesis. It is routinely used to mobilize CD34+ hematopoietic stem cells from the BM into peripheral blood, thus enabling their easier collection compared to BM aspirate procedure. The proven efficacy and safety of G-CSF, both in healthy donors and patients with haematological disease, along with favourable results from studies of CD34+ cell transplantation in patients with MI or ischemia, suggest that G-CSF based BMC transplantation may have an efficacy in patients with MI.
Obesity, especially central obesity is associated with increased risk of metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus. The study aimed to investigate the associations of the changes of abdominal fat thicknesses with changes of anthropometric indexes and improvements of metabolic phenotypes in patients with obesity and T2DM before and after bariatric surgery. Between April 2016 and January 2017, 34 adult patients with concurrent obesity and T2DM scheduled for different bariatric surgeries were prospectively evaluated by ultrasound before and 1-year after bariatric surgery to determine abdominal fat thicknesses (mesenteric fat, preperitoneal fat and subcutaneous fat) and NAFLD. At 1 year, of the 25 patients that finished the study, significant decrease in mesenteric-fat-thickness was associated with significant reduction of obesity, that is, BMI (-24%, p < .001), remission of metabolic syndrome (32%, p = .008), NAFLD (60%, p < .001) and T2DM (44%, p < .001). Lower baseline mesenteric fat thickness was associated with remission of metabolic syndrome. Lower baseline mesenteric-fat-thickness may have the potential to predict metabolic syndrome remission after bariatric surgery.